WaveMan
WaveMan · Company
PRLD · Prelude Therapeutics Inc
> Search tickers & screens ⌘K
LIVE
← All companies

PRLD Prelude Therapeutics (PRLD) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001678660
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
60
13F, latest reported quarter

Prelude Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Prelude Therapeutics Inc in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Bonita David P
Director
BUY
2026-04-23 SECtraded 2026-04-21
1,689,189
$7.5M
-22.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 22, 2023.
  • The trade is 14.3% of the 11,808,945 shares held after it.
  • 1 other insider bought within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bonita David P bought about $7.5M of PRLD on Apr 21, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 60 funds added in the latest 13F quarter.
Bonita David P
Director
BUY
2026-04-23 SECtraded 2026-04-21
1,126,126
$5.0M
-22.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 22, 2023.
  • The trade is 100.0% of the 1,126,126 shares held after it.
  • 1 other insider bought within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bonita David P bought about $5.0M of PRLD on Apr 21, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 60 funds added in the latest 13F quarter.
OrbiMed Genesis GP LLC
Director
BUY
2026-04-23 SECtraded 2026-04-21
1,689,189
$7.5M
-22.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 14.3% of the 11,808,945 shares held after it.
  • 1 other insider bought within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director OrbiMed Genesis GP LLC bought about $7.5M of PRLD on Apr 21, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 60 funds added in the latest 13F quarter.
OrbiMed Genesis GP LLC
Director
BUY
2026-04-23 SECtraded 2026-04-21
1,126,126
$5.0M
-22.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 1,126,126 shares held after it.
  • 1 other insider bought within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director OrbiMed Genesis GP LLC bought about $5.0M of PRLD on Apr 21, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 60 funds added in the latest 13F quarter.
Combs Andrew
Chief Chemistry Officer
BUY
2025-03-27 SECtraded 2025-03-25
100,000
$69.0K
+353.8%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Dec 23, 2024.
  • -39.0% median (-39.0% mean) 90-day return after 4 previous buys.
  • The trade is 20.8% of the 480,123 shares held after it.
  • 1 other insider bought within 30 days.
  • 60 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Chemistry Officer Combs Andrew bought about $69.0K of PRLD on Mar 25, 2025; 1 other insider bought within 30 days and 60 funds added in the latest 13F quarter.
61 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 56 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
60 funds bought in last quarter
more than 51% of Pharma & Biotech
Revenue
+73.4% year over year
more than 82% of Pharma & Biotech
Margin
-819.6% net margin
below 83% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
20.7% of the float short (float per yahoo 2026-10-26) · 7.9 days to cover · settled 2026-09-30
more than 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PRLD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+129.7%12M
-25%+90%+205%+320%2025-102025-122026-022026-042026-062026-082026-10 2026-04-21 · Bonita David P bought $7.5M2026-04-21 · OrbiMed Genesis GP LLC bought $7.5M2026-04-21 · Bonita David P bought $5.0M2026-04-21 · OrbiMed Genesis GP LLC bought $5.0M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PRLD: institutional holders (13F)

13F holdings, latest reported quarter
ORBIMED ADVISORS LLC
13,724,571 sh
$73.2M
BAKER BROS. ADVISORS LP
10,123,824 sh
$54.0M
RA CAPITAL MANAGEMENT, L.P.
6,475,882 sh
$34.5M
Soleus Capital Management, L.P.
3,378,378 sh
$18.0M
Kynam Capital Management, LP
2,415,087 sh
$12.9M

Congress trades in PRLD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PRLD planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PRLD mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$325.1K position · as of 2026-06-30
0.2%
SIIT SMALL CAP II FUND
$321.8K position · as of 2026-05-31
0.1%
SIMT Tax-Managed Small/Mid Cap Fund
$970.7K position · as of 2026-06-30
0.1%
Goldman Sachs Small Cap Growth Insights Fund
$119.2K position · as of 2026-07-31
0.0%
Small Company Growth Portfolio
$9.1K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$496.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
11 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
10
Phase 1
1 active
1
Phase 2
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.3M
$2.4M
$833.6K
-32%
n/a
2024
$2.3M
$448.0K
$1.3M
-70%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 60 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PRLD financials

Revenue growth
+73.4%
XBRL, annual
Net margin
-819.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$22.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-269.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$33.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-57.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-39.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-54.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-11.5%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$12.1M$7.0Mn/an/a
Operating income-$104.6M-$139.7M-$132.3M-$123.5M
Net income-$99.5M-$127.2M-$121.8M-$115.4M
EPS (diluted)-1.29-1.68-2.02-2.44
Operating cash flow-$56.3M-$102.9M-$107.1M-$83.7M
Cash$35.3M$12.5M$25.3M$30.6M
SEC XBRL, fiscal years, as known on 2026-10-27

PRLD Stock Sonar score 4/7 axes

Find similar shapesCompare

PRLD ranks highest on growth (82nd percentile) and institutional and government (51st), and lowest on risk and compliance (40th), among Pharma & Biotech peers.

Profitability
50
Inputs
  • Return on equity-57.7% · 50 pct, sector of 545
  • Return on assets-39.8% · 53 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-54.9% · 46 pct, sector of 576
Growth
82
Inputs
  • Revenue growth, YoY+73.4% · 82 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
51
Inputs
  • Funds adding, latest quarter60 · 51 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
40
Inputs
  • Short interest, % of float+20.7% · 14 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.7% · 66 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies